Analysis of Topical Cyclosporine Treatment of Patients With Dry Eye SyndromeEffect on Conjunctival Lymphocytes

We found that CsA treatment reduced the number of activated T lymphocytes within the ocular surface of patients with and without Sjögren syndrome

Kathleen S. Kunert

2012

Scholarcy highlights

  • Following treatment with 0.05% cyclosporine, there was a significant decrease in the number of cells expressing the lymphocyte activation markers CD11a and HLA-DR
  • Biopsy specimens were obtained at baseline and after 6 months of cyclosporine treatment from eyes of 32 patients with moderate to severe dry eye syndrome; 19 were cyclosporine treated and 13 were vehicle treated
  • (P,.05), indicating less activation of lymphocytes as compared with vehicle treatment
  • Treatment of dry eye syndrome with topical cyclosporine significantly reduced the numbers of activated lymphocytes within the conjunctiva
  • We found that CsA treatment reduced the number of activated T lymphocytes within the ocular surface of patients with and without Sjögren syndrome
  • Pairwise comparisons showed significant reductions with 0.05% CsA treatment compared with treatment with vehicle in cells positive for both markers CD11a and HLA-DR
  • Even though the reduction in Pan-T cells and CD11a seems to be larger in patients with Sjögren syndrome, our data on the lymphocyte activation markers, especially HLA-DR, provide evidence that CsA treatment is providing benefits for both types of dry eye syndrome

Need more features? Save interactive summary cards to your Scholarcy Library.